PCIDB

KNApSAcK Metabolite C00000208

Metabolite

KNApSAcK Entry

id C00000208
Name Nicotinic acid
CAS RN 59-67-6
Standard InChI InChI=1S/C6H5NO2/c8-6(9)5-2-1-3-7-4-5/h1-4H,(H,8,9)
Standard InChI (Main Layer) InChI=1S/C6H5NO2/c8-6(9)5-2-1-3-7-4-5/h1-4H,(H,8,9)

Cluster

Phytochemical cluster No. 1
KCF-S cluster No. 3681

Link

ChEMBL

By standard InChI CHEMBL573
By standard InChI Main Layer CHEMBL573 CHEMBL2074803

KEGG

By LinkDB C00253

CTD

By CAS RN D009525

Human Protein / Gene in interaction

100 ChEMBL Protein in interactions

accession description class description compound assay ID (# of activities) # of diseases
(OMIM / KEGG)
P10635 Cytochrome P450 2D6 Cytochrome P450 2D6 CHEMBL573 CHEMBL1741321 (1) CHEMBL1909136 (2)
CHEMBL2071965 (1)
1 / 0
Q9UIF8 Bromodomain adjacent to zinc finger domain protein 2B Unclassified protein CHEMBL573 CHEMBL1738312 (1)
0 / 0
O94956 Solute carrier organic anion transporter family member 2B1 Unclassified protein CHEMBL2074803 CHEMBL2077323 (1)
0 / 0
Q96FL8 Multidrug and toxin extrusion protein 1 Cation antiporter CHEMBL573 CHEMBL2320305 (1) CHEMBL2320306 (1)
0 / 0
P21728 D(1A) dopamine receptor Dopamine receptor CHEMBL573 CHEMBL1909139 (2)
0 / 0
P35354 Prostaglandin G/H synthase 2 Oxidoreductase CHEMBL573 CHEMBL1014033 (1) CHEMBL1909131 (2)
0 / 3
Q12809 Potassium voltage-gated channel subfamily H member 2 KCNH, Kv10-12.x (Ether-a-go-go) CHEMBL573 CHEMBL1909190 (2)
2 / 2
P08246 Neutrophil elastase S1A CHEMBL573 CHEMBL1909195 (2)
2 / 1
P33765 Adenosine receptor A3 Adenosine receptor CHEMBL573 CHEMBL1909215 (2)
0 / 0
Q16539 Mitogen-activated protein kinase 14 p38 CHEMBL573 CHEMBL1909201 (2)
0 / 0
P49146 Neuropeptide Y receptor type 2 Neuropeptide Y receptor CHEMBL573 CHEMBL1909176 (2)
0 / 0
P10253 Lysosomal alpha-glucosidase Hydrolase CHEMBL573 CHEMBL1614103 (1) CHEMBL1614031 (1)
1 / 1
P29466 Caspase-1 C14 CHEMBL573 CHEMBL1909193 (2)
0 / 0
P17252 Protein kinase C alpha type Alpha CHEMBL573 CHEMBL1909198 (2)
0 / 0
P27361 Mitogen-activated protein kinase 3 Erk CHEMBL573 CHEMBL1909199 (2)
0 / 0
P14780 Matrix metalloproteinase-9 M10A CHEMBL573 CHEMBL1909197 (2)
2 / 2
P00918 Carbonic anhydrase 2 Lyase CHEMBL573 CHEMBL1909123 (2)
1 / 2
P07550 Beta-2 adrenergic receptor Adrenergic receptor CHEMBL573 CHEMBL1909092 (2)
0 / 1
P21397 Amine oxidase [flavin-containing] A Oxidoreductase CHEMBL573 CHEMBL1909169 (2)
1 / 1
P25021 Histamine H2 receptor Histamine receptor CHEMBL573 CHEMBL1909157 (2)
0 / 0
P35367 Histamine H1 receptor Histamine receptor CHEMBL573 CHEMBL1909156 (2)
0 / 0
Q01959 Sodium-dependent dopamine transporter Dopamine CHEMBL573 CHEMBL1909143 (2)
1 / 0
P08912 Muscarinic acetylcholine receptor M5 Acetylcholine receptor CHEMBL573 CHEMBL1909174 (2)
0 / 0
P18825 Alpha-2C adrenergic receptor Adrenergic receptor CHEMBL573 CHEMBL1909090 (2)
0 / 0
P13945 Beta-3 adrenergic receptor Adrenergic receptor CHEMBL573 CHEMBL1909093 (2)
0 / 0
P25024 C-X-C chemokine receptor type 1 CXC chemokine receptor CHEMBL573 CHEMBL1909127 (2)
0 / 0
P06241 Tyrosine-protein kinase Fyn Src CHEMBL573 CHEMBL1909204 (2)
0 / 0
Q08209 Serine/threonine-protein phosphatase 2B catalytic subunit alpha isoform Ser_Thr CHEMBL573 CHEMBL1909202 (2)
0 / 0
P11712 Cytochrome P450 2C9 Cytochrome P450 2C9 CHEMBL573 CHEMBL1741325 (1) CHEMBL1909135 (2)
CHEMBL2071963 (1)
0 / 1
P00533 Epidermal growth factor receptor TK tyrosine-protein kinase EGFR subfamily CHEMBL573 CHEMBL1909203 (2)
1 / 11
P14416 D(2) dopamine receptor Dopamine receptor CHEMBL573 CHEMBL1909140 (2)
2 / 0
P23219 Prostaglandin G/H synthase 1 Oxidoreductase CHEMBL573 CHEMBL1909130 (2)
0 / 0
P37288 Vasopressin V1a receptor Vasopressin and oxytocin receptor CHEMBL573 CHEMBL1909120 (2)
0 / 0
P41145 Kappa-type opioid receptor Opioid receptor CHEMBL573 CHEMBL1909181 (2)
0 / 0
Q9Y271 Cysteinyl leukotriene receptor 1 Leukotriene receptor CHEMBL573 CHEMBL1909164 (2)
0 / 0
P29274 Adenosine receptor A2a Adenosine receptor CHEMBL573 CHEMBL1909214 (2)
0 / 0
P25929 Neuropeptide Y receptor type 1 Neuropeptide Y receptor CHEMBL573 CHEMBL1909175 (2)
0 / 0
P50052 Type-2 angiotensin II receptor Angiotensin receptor CHEMBL573 CHEMBL1909096 (2)
1 / 1
P17948 Vascular endothelial growth factor receptor 1 Vegfr CHEMBL573 CHEMBL1909118 (2)
0 / 0
P41968 Melanocortin receptor 3 Melanocortin receptor CHEMBL573 CHEMBL1909166 (2)
1 / 0
P00352 Retinal dehydrogenase 1 Enzyme CHEMBL573 CHEMBL1614458 (1)
0 / 0
P11509 Cytochrome P450 2A6 Cytochrome P450 2A6 CHEMBL573 CHEMBL1909133 (2)
0 / 0
Q8TDS4 Hydroxycarboxylic acid receptor 2 Hydroxycarboxylic acid receptor CHEMBL573 CHEMBL915842 (1) CHEMBL899634 (2)
CHEMBL899641 (1) CHEMBL900196 (1)
CHEMBL900197 (1) CHEMBL900198 (1)
CHEMBL924060 (1) CHEMBL944044 (1)
CHEMBL944045 (1) CHEMBL921658 (1)
CHEMBL921659 (1) CHEMBL921666 (1)
CHEMBL933836 (1) CHEMBL971506 (1)
CHEMBL971521 (1) CHEMBL971522 (1)
CHEMBL971523 (1) CHEMBL1002177 (1)
CHEMBL981701 (1) CHEMBL981702 (1)
CHEMBL981703 (1) CHEMBL983496 (1)
CHEMBL983499 (1) CHEMBL1064087 (1)
CHEMBL1064094 (1) CHEMBL1054335 (1)
CHEMBL1054337 (1) CHEMBL1054340 (1)
CHEMBL1054354 (1) CHEMBL1105987 (1)
CHEMBL1105988 (1) CHEMBL1105991 (1)
CHEMBL1118308 (1) CHEMBL1118502 (1)
CHEMBL1120319 (1) CHEMBL1117820 (1)
CHEMBL1119082 (1) CHEMBL1119525 (1)
CHEMBL1211914 (1) CHEMBL1680944 (1)
CHEMBL1943806 (1) CHEMBL2037944 (1)
CHEMBL2060037 (1) CHEMBL2060038 (1)
CHEMBL2150704 (1)
0 / 0
Q9BXC0 Hydroxycarboxylic acid receptor 1 Hydroxycarboxylic acid receptor CHEMBL573 CHEMBL2150705 (1)
0 / 0
P04035 3-hydroxy-3-methylglutaryl-coenzyme A reductase Oxidoreductase CHEMBL573 CHEMBL1909158 (2)
0 / 0
P08913 Alpha-2A adrenergic receptor Adrenergic receptor CHEMBL573 CHEMBL1909088 (2)
0 / 0
P21917 D(4) dopamine receptor Dopamine receptor CHEMBL573 CHEMBL1909142 (2)
0 / 0
P30988 Calcitonin receptor Calcitonin receptor CHEMBL573 CHEMBL1909101 (2)
0 / 0
P35462 D(3) dopamine receptor Dopamine receptor CHEMBL573 CHEMBL1909141 (2)
1 / 0
P41143 Delta-type opioid receptor Opioid receptor CHEMBL573 CHEMBL1909180 (2)
0 / 0
Q92731 Estrogen receptor beta NR3A2 CHEMBL573 CHEMBL1909146 (2)
0 / 1
P41595 5-hydroxytryptamine receptor 2B Serotonin receptor CHEMBL573 CHEMBL1909104 (2)
0 / 0
P25101 Endothelin-1 receptor Endothelin receptor CHEMBL573 CHEMBL1909144 (2)
0 / 0
P30411 B2 bradykinin receptor Bradykinin receptor CHEMBL573 CHEMBL1909100 (2)
0 / 0
P32245 Melanocortin receptor 4 Melanocortin receptor CHEMBL573 CHEMBL1909167 (2)
1 / 0
P32238 Cholecystokinin receptor type A Cholecystokinin receptor CHEMBL573 CHEMBL1909129 (2)
0 / 0
P08311 Cathepsin G S1A CHEMBL573 CHEMBL1909194 (2)
0 / 0
Q99720 Sigma non-opioid intracellular receptor 1 Membrane receptor CHEMBL573 CHEMBL1909110 (2)
1 / 0
P43220 Glucagon-like peptide 1 receptor Glucagon-like peptide receptor CHEMBL573 CHEMBL2114931 (1)
0 / 0
P03956 Interstitial collagenase M10A CHEMBL573 CHEMBL1909196 (2)
0 / 1
P32241 Vasoactive intestinal polypeptide receptor 1 Vasoactive intestinal peptide receptor CHEMBL573 CHEMBL1909119 (2)
0 / 0
P04150 Glucocorticoid receptor NR3C1 CHEMBL573 CHEMBL1909150 (2)
0 / 1
P08172 Muscarinic acetylcholine receptor M2 Acetylcholine receptor CHEMBL573 CHEMBL1909171 (2)
2 / 0
P11229 Muscarinic acetylcholine receptor M1 Acetylcholine receptor CHEMBL573 CHEMBL1909170 (2)
0 / 0
P21554 Cannabinoid receptor 1 Cannabinoid receptor CHEMBL573 CHEMBL1909122 (2)
0 / 0
P31645 Sodium-dependent serotonin transporter Serotonin CHEMBL573 CHEMBL1909109 (2)
2 / 0
P04626 Receptor tyrosine-protein kinase erbB-2 TK tyrosine-protein kinase EGFR subfamily CHEMBL573 CHEMBL1909205 (2)
5 / 10
P20309 Muscarinic acetylcholine receptor M3 Acetylcholine receptor CHEMBL573 CHEMBL1909172 (2)
1 / 0
P21452 Substance-K receptor Neurokinin receptor CHEMBL573 CHEMBL1909114 (2)
0 / 0
P51679 C-C chemokine receptor type 4 CC chemokine receptor CHEMBL573 CHEMBL1909125 (2)
0 / 0
P51681 C-C chemokine receptor type 5 CC chemokine receptor CHEMBL573 CHEMBL1909126 (2)
3 / 0
P50406 5-hydroxytryptamine receptor 6 Serotonin receptor CHEMBL573 CHEMBL1909108 (2)
0 / 0
P41597 C-C chemokine receptor type 2 CC chemokine receptor CHEMBL573 CHEMBL1909124 (2)
1 / 0
P28482 Mitogen-activated protein kinase 1 Erk CHEMBL573 CHEMBL1909200 (2)
0 / 0
P08575 Receptor-type tyrosine-protein phosphatase C Enzyme CHEMBL573 CHEMBL1909207 (2)
2 / 1
P05177 Cytochrome P450 1A2 Cytochrome P450 1A2 CHEMBL573 CHEMBL1741322 (1) CHEMBL1909132 (2)
CHEMBL2071962 (1)
0 / 0
O76074 cGMP-specific 3',5'-cyclic phosphodiesterase PDE_5A CHEMBL573 CHEMBL1909186 (2)
0 / 0
P03372 Estrogen receptor NR3A1 CHEMBL573 CHEMBL1909145 (2)
1 / 1
P08588 Beta-1 adrenergic receptor Adrenergic receptor CHEMBL573 CHEMBL1909091 (2)
1 / 0
P22303 Acetylcholinesterase Hydrolase CHEMBL573 CHEMBL1909212 (2)
1 / 0
P28223 5-hydroxytryptamine receptor 2A Serotonin receptor CHEMBL573 CHEMBL1909211 (2)
0 / 0
P28335 5-hydroxytryptamine receptor 2C Serotonin receptor CHEMBL573 CHEMBL1909105 (2)
0 / 0
P35372 Mu-type opioid receptor Opioid receptor CHEMBL573 CHEMBL1909182 (2)
0 / 0
P08173 Muscarinic acetylcholine receptor M4 Acetylcholine receptor CHEMBL573 CHEMBL1909173 (2)
0 / 0
P25103 Substance-P receptor Neurokinin receptor CHEMBL573 CHEMBL1909113 (2)
0 / 0
P25105 Platelet-activating factor receptor PAF receptor CHEMBL573 CHEMBL1909187 (2)
0 / 0
P33032 Melanocortin receptor 5 Melanocortin receptor CHEMBL573 CHEMBL1909168 (2)
0 / 0
P33261 Cytochrome P450 2C19 Cytochrome P450 2C19 CHEMBL573 CHEMBL1741323 (1) CHEMBL1909134 (2)
CHEMBL2071964 (1)
1 / 1
P08684 Cytochrome P450 3A4 Cytochrome P450 3A4 CHEMBL573 CHEMBL1741324 (1) CHEMBL1909138 (2)
CHEMBL2071966 (1) CHEMBL2071967 (1)
0 / 1
P05181 Cytochrome P450 2E1 Cytochrome P450 2E1 CHEMBL573 CHEMBL1909137 (2)
0 / 0
P49019 Hydroxycarboxylic acid receptor 3 Hydroxycarboxylic acid receptor CHEMBL573 CHEMBL915843 (1) CHEMBL915844 (1)
CHEMBL899635 (1) CHEMBL899636 (1)
CHEMBL924061 (1) CHEMBL1118503 (1)
CHEMBL1680932 (1) CHEMBL2037945 (1)
CHEMBL2060039 (1)
0 / 0
O75164 Lysine-specific demethylase 4A Enzyme CHEMBL573 CHEMBL1737991 (1)
0 / 0
P23975 Sodium-dependent noradrenaline transporter Norepinephrine CHEMBL573 CHEMBL1909094 (2)
1 / 1
P25100 Alpha-1D adrenergic receptor Adrenergic receptor CHEMBL573 CHEMBL1909087 (2)
0 / 0
P30542 Adenosine receptor A1 Adenosine receptor CHEMBL573 CHEMBL1909213 (2)
0 / 0
P18089 Alpha-2B adrenergic receptor Adrenergic receptor CHEMBL573 CHEMBL1909089 (2)
0 / 0
P24557 Thromboxane-A synthase Cytochrome P450 5A1 CHEMBL573 CHEMBL1909116 (2)
1 / 1
P06239 Tyrosine-protein kinase Lck Src CHEMBL573 CHEMBL1909206 (2)
0 / 1
P25025 C-X-C chemokine receptor type 2 CXC chemokine receptor CHEMBL573 CHEMBL1909128 (2)
0 / 0
O76082 Solute carrier family 22 member 5 Unclassified protein CHEMBL2074803 CHEMBL2078114 (1)
1 / 2

CTD interaction (107)

compound gene gene name gene description interaction interaction type form reference
pmid
D009525 19 ABCA1
ABC-1
ABC1
CERP
HDLDT1
TGD
ATP-binding cassette, sub-family A (ABC1), member 1 [Chromium co-treated with Niacin] results in decreased expression of ABCA1 mRNA affects cotreatment
/ decreases expression
mRNA 18602814
D009525 19 ABCA1
ABC-1
ABC1
CERP
HDLDT1
TGD
ATP-binding cassette, sub-family A (ABC1), member 1 Niacin results in increased expression of ABCA1 mRNA increases expression
mRNA 15037193
18602814
D009525 9370 ADIPOQ
ACDC
ACRP30
ADIPQTL1
ADPN
APM-1
APM1
GBP28
adiponectin, C1Q and collagen domain containing Niacin promotes the reaction [ADIPOQ protein binds to ADIPOQ protein] affects binding
/ increases reaction
protein 17996241
18249215
D009525 9370 ADIPOQ
ACDC
ACRP30
ADIPQTL1
ADPN
APM-1
APM1
GBP28
adiponectin, C1Q and collagen domain containing Niacin results in increased expression of ADIPOQ mRNA increases expression
mRNA 19131065
D009525 9370 ADIPOQ
ACDC
ACRP30
ADIPQTL1
ADPN
APM-1
APM1
GBP28
adiponectin, C1Q and collagen domain containing Niacin results in increased expression of ADIPOQ protein increases expression
protein 16887123
16979396
17996241
18249215
19131065
D009525 183 AGT
ANHU
SERPINA8
angiotensinogen (serpin peptidase inhibitor, clade A, member 8) Niacin inhibits the reaction [AGT protein results in increased abundance of Reactive Oxygen Species] decreases reaction
/ increases abundance
protein 18550065
D009525 197 AHSG
A2HS
AHS
FETUA
HSGA
alpha-2-HS-glycoprotein Niacin results in decreased expression of and results in decreased phosphorylation of AHSG protein decreases expression
/ decreases phosphorylation
protein 19405044
D009525 335 APOA1
apolipoprotein A-I [Chromium co-treated with Niacin] results in increased expression of APOA1 mRNA affects cotreatment
/ increases expression
mRNA 18602814
D009525 335 APOA1
apolipoprotein A-I [Lovastatin co-treated with Niacin] results in increased expression of APOA1 protein affects cotreatment
/ increases expression
protein 17319473
D009525 335 APOA1
apolipoprotein A-I [Niacin co-treated with ezetimibe co-treated with Simvastatin] results in increased expression of APOA1 protein affects cotreatment
/ increases expression
protein 20152243
D009525 335 APOA1
apolipoprotein A-I [Niacin co-treated with Lovastatin] results in increased expression of APOA1 protein affects cotreatment
/ increases expression
protein 12633795
D009525 335 APOA1
apolipoprotein A-I Niacin promotes the reaction [rosuvastatin results in increased expression of APOA1 protein] increases expression
/ increases reaction
protein 12767421
15539964
D009525 335 APOA1
apolipoprotein A-I Niacin promotes the reaction [[Simvastatin co-treated with ezetimibe] results in increased expression of APOA1 protein] affects cotreatment
/ increases expression
/ increases reaction
protein 18420099
D009525 335 APOA1
apolipoprotein A-I Niacin results in increased expression of APOA1 protein increases expression
protein 11701466
12767421
15539964
18566298
D009525 338 APOB
FLDB
LDLCQ4
apolipoprotein B [Niacin co-treated with Lovastatin] results in decreased expression of APOB protein affects cotreatment
/ decreases expression
protein 12633795
D009525 338 APOB
FLDB
LDLCQ4
apolipoprotein B [Niacin co-treated with Simvastatin] results in decreased expression of APOB protein affects cotreatment
/ decreases expression
protein 18471454
D009525 338 APOB
FLDB
LDLCQ4
apolipoprotein B Niacin results in decreased expression of APOB protein decreases expression
protein 11701466
15539964
D009525 506 ATP5B
ATPMB
ATPSB
ATP synthase, H+ transporting, mitochondrial F1 complex, beta polypeptide (EC:3.6.3.14) Niacin results in decreased expression of ATP5B protein decreases expression
protein 18316796
D009525 6347 CCL2
GDCF-2
HC11
HSMCR30
MCAF
MCP-1
MCP1
SCYA2
SMC-CF
chemokine (C-C motif) ligand 2 Niacin inhibits the reaction [TNF protein results in increased expression of CCL2 protein] decreases reaction
/ increases expression
protein 18550065
D009525 6347 CCL2
GDCF-2
HC11
HSMCR30
MCAF
MCP-1
MCP1
SCYA2
SMC-CF
chemokine (C-C motif) ligand 2 Niacin results in decreased expression of CCL2 protein decreases expression
protein 18550065
D009525 1050 CEBPA
C/EBP-alpha
CEBP
CCAAT/enhancer binding protein (C/EBP), alpha Niacin results in increased expression of CEBPA mRNA increases expression
mRNA 19131065
D009525 1052 CEBPD
C/EBP-delta
CELF
CRP3
NF-IL6-beta
CCAAT/enhancer binding protein (C/EBP), delta Niacin results in increased expression of CEBPD mRNA increases expression
mRNA 19131065
D009525 1376 CPT2
CPT1
CPTASE
IIAE4
carnitine palmitoyltransferase 2 (EC:2.3.1.21) Niacin results in decreased expression of CPT2 mRNA decreases expression
mRNA 19131065
D009525 1401 CRP
PTX1
C-reactive protein, pentraxin-related Niacin results in decreased expression of CRP protein decreases expression
protein 16950175
18420099
D009525 1401 CRP
PTX1
C-reactive protein, pentraxin-related [Simvastatin co-treated with ezetimibe] promotes the reaction [Niacin results in decreased expression of CRP protein] affects cotreatment
/ decreases expression
/ increases reaction
protein 18420099
D009525 84649 DGAT2
ARAT
GS1999FULL
diacylglycerol O-acyltransferase 2 (EC:2.3.1.20 2.3.1.76) Niacin results in decreased activity of DGAT2 protein decreases activity
protein 15258194
D009525 84649 DGAT2
ARAT
GS1999FULL
diacylglycerol O-acyltransferase 2 (EC:2.3.1.20 2.3.1.76) [Niacin results in decreased activity of DGAT2 protein] which results in decreased chemical synthesis of Triglycerides decreases activity
/ decreases chemical synthesis
protein 15258194
D009525 2149 F2R
CF2R
HTR
PAR-1
PAR1
TR
coagulation factor II (thrombin) receptor Niacin results in increased expression of F2R protein increases expression
protein 20539903
D009525 2194 FASN
FAS
OA-519
SDR27X1
fatty acid synthase (EC:2.3.1.85 2.3.1.38 2.3.1.39 2.3.1.41 3.1.2.14 4.2.1.59 1.1.1.100 1.3.1.39) Niacin results in decreased expression of FASN mRNA decreases expression
mRNA 19131065
D009525 2641 GCG
GLP1
GLP2
GRPP
glucagon Glucose inhibits the reaction [[Niacin results in decreased abundance of Fatty Acids, Nonesterified] which results in increased secretion of GCG protein] decreases abundance
/ decreases reaction
/ increases secretion
protein 838844
D009525 2641 GCG
GLP1
GLP2
GRPP
glucagon [Niacin results in decreased abundance of Fatty Acids, Nonesterified] which results in increased secretion of GCG protein decreases abundance
/ increases secretion
protein 838844
D009525 2688 GH1
GH
GH-N
GHN
IGHD1B
hGH-N
growth hormone 1 Glucose inhibits the reaction [[Niacin results in decreased abundance of Fatty Acids, Nonesterified] which results in increased secretion of GH1 protein] decreases abundance
/ decreases reaction
/ increases secretion
protein 838844
D009525 2688 GH1
GH
GH-N
GHN
IGHD1B
hGH-N
growth hormone 1 [Niacin results in decreased abundance of Fatty Acids, Nonesterified] which results in increased secretion of GH1 protein decreases abundance
/ increases secretion
protein 838844
D009525 338442 HCAR2
GPR109A
HCA2
HM74a
HM74b
NIACR1
PUMAG
Puma-g
hydroxycarboxylic acid receptor 2 HCAR2 protein promotes the reaction [Niacin results in increased expression of and results in increased activity of PPARG protein] increases activity
/ increases expression
/ increases reaction
protein 16386710
D009525 338442 HCAR2
GPR109A
HCA2
HM74a
HM74b
NIACR1
PUMAG
Puma-g
hydroxycarboxylic acid receptor 2 Niacin binds to and affects the activity of HCAR2 protein affects activity
/ affects binding
protein 16018973
D009525 338442 HCAR2
GPR109A
HCA2
HM74a
HM74b
NIACR1
PUMAG
Puma-g
hydroxycarboxylic acid receptor 2 Niacin binds to and results in increased activity of HCAR2 protein affects binding
/ increases activity
protein 16389067
20380810
20452209
20460384
21167710
D009525 338442 HCAR2
GPR109A
HCA2
HM74a
HM74b
NIACR1
PUMAG
Puma-g
hydroxycarboxylic acid receptor 2 [Niacin binds to and results in increased activity of HCAR2 protein] which results in increased phosphorylation of MAPK1 protein affects binding
/ increases activity
/ increases phosphorylation
protein 16389067
D009525 338442 HCAR2
GPR109A
HCA2
HM74a
HM74b
NIACR1
PUMAG
Puma-g
hydroxycarboxylic acid receptor 2 [Niacin binds to and results in increased activity of HCAR2 protein] which results in increased phosphorylation of MAPK3 protein affects binding
/ increases activity
/ increases phosphorylation
protein 16389067
D009525 338442 HCAR2
GPR109A
HCA2
HM74a
HM74b
NIACR1
PUMAG
Puma-g
hydroxycarboxylic acid receptor 2 Niacin binds to HCAR2 protein affects binding
protein 16099840
D009525 338442 HCAR2
GPR109A
HCA2
HM74a
HM74b
NIACR1
PUMAG
Puma-g
hydroxycarboxylic acid receptor 2 Niacin results in increased activity of HCAR2 protein increases activity
protein 15929991
19223991
D009525 338442 HCAR2
GPR109A
HCA2
HM74a
HM74b
NIACR1
PUMAG
Puma-g
hydroxycarboxylic acid receptor 2 [Niacin results in increased activity of HCAR2 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP] decreases reaction
/ increases abundance
/ increases activity
protein 19223991
D009525 8843 HCAR3
GPR109B
HCA3
HM74
PUMAG
Puma-g
hydroxycarboxylic acid receptor 3 HCAR3 protein promotes the reaction [Niacin results in increased activity of PPARG protein] increases activity
/ increases reaction
protein 16386710
D009525 8843 HCAR3
GPR109B
HCA3
HM74
PUMAG
Puma-g
hydroxycarboxylic acid receptor 3 Niacin binds to and results in increased activity of HCAR3 protein affects binding
/ increases activity
protein 16389067
D009525 8843 HCAR3
GPR109B
HCA3
HM74
PUMAG
Puma-g
hydroxycarboxylic acid receptor 3 [Niacin binds to and results in increased activity of HCAR3 protein] which results in increased phosphorylation of MAPK1 protein affects binding
/ increases activity
/ increases phosphorylation
protein 16389067
D009525 8843 HCAR3
GPR109B
HCA3
HM74
PUMAG
Puma-g
hydroxycarboxylic acid receptor 3 [Niacin binds to and results in increased activity of HCAR3 protein] which results in increased phosphorylation of MAPK3 protein affects binding
/ increases activity
/ increases phosphorylation
protein 16389067
D009525 8843 HCAR3
GPR109B
HCA3
HM74
PUMAG
Puma-g
hydroxycarboxylic acid receptor 3 Niacin binds to HCAR3 protein affects binding
protein 16480258
D009525 3383 ICAM1
BB2
CD54
P3.58
intercellular adhesion molecule 1 Niacin inhibits the reaction [IFNG protein results in increased expression of ICAM1 protein] decreases reaction
/ increases expression
protein 19159436
D009525 3383 ICAM1
BB2
CD54
P3.58
intercellular adhesion molecule 1 Niacin inhibits the reaction [IL1B protein results in increased expression of ICAM1 protein] decreases reaction
/ increases expression
protein 19159436
D009525 3383 ICAM1
BB2
CD54
P3.58
intercellular adhesion molecule 1 Niacin inhibits the reaction [TNF protein results in increased expression of ICAM1 mRNA] decreases reaction
/ increases expression
mRNA 16916501
19159436
D009525 3383 ICAM1
BB2
CD54
P3.58
intercellular adhesion molecule 1 Niacin results in decreased expression of ICAM1 protein decreases expression
protein 19159436
D009525 3458 IFNG
IFG
IFI
interferon, gamma Niacin inhibits the reaction [IFNG protein results in increased expression of ICAM1 protein] decreases reaction
/ increases expression
protein 19159436
D009525 3553 IL1B
IL-1
IL1-BETA
IL1F2
interleukin 1, beta Niacin inhibits the reaction [IL1B protein results in increased expression of ICAM1 protein] decreases reaction
/ increases expression
protein 19159436
D009525 3553 IL1B
IL-1
IL1-BETA
IL1F2
interleukin 1, beta [Ubiquinone co-treated with Niacin co-treated with Riboflavin] promotes the reaction [Tamoxifen results in decreased expression of IL1B protein] affects cotreatment
/ decreases expression
/ increases reaction
protein 17516992
D009525 3569 IL6
BSF2
HGF
HSF
IFNB2
IL-6
interleukin 6 (interferon, beta 2) [Ubiquinone co-treated with Niacin co-treated with Riboflavin] promotes the reaction [Tamoxifen results in decreased expression of IL6 protein] affects cotreatment
/ decreases expression
/ increases reaction
protein 17516992
D009525 3576 IL8
CXCL8
GCP-1
GCP1
LECT
LUCT
LYNAP
MDNCF
MONAP
NAF
NAP-1
NAP1
interleukin 8 [Ubiquinone co-treated with Niacin co-treated with Riboflavin] promotes the reaction [Tamoxifen results in decreased expression of IL8 protein] affects cotreatment
/ decreases expression
/ increases reaction
protein 17516992
D009525 3952 LEP
LEPD
OB
OBS
leptin Niacin results in increased expression of LEP protein increases expression
protein 16887123
D009525 3991 LIPE
HSL
LHS
lipase, hormone-sensitive (EC:3.1.1.79) Niacin results in decreased activity of LIPE protein decreases activity
protein 14749208
D009525 3991 LIPE
HSL
LHS
lipase, hormone-sensitive (EC:3.1.1.79) Niacin results in decreased expression of LIPE mRNA decreases expression
mRNA 19131065
D009525 4018 LPA
AK38
APOA
LP
lipoprotein, Lp(a) (EC:3.4.21.-) [Lovastatin co-treated with Niacin] results in decreased expression of LPA protein affects cotreatment
/ decreases expression
protein 17319473
D009525 4018 LPA
AK38
APOA
LP
lipoprotein, Lp(a) (EC:3.4.21.-) [Niacin co-treated with Lovastatin] results in decreased expression of LPA protein affects cotreatment
/ decreases expression
protein 12633795
D009525 4018 LPA
AK38
APOA
LP
lipoprotein, Lp(a) (EC:3.4.21.-) [Niacin co-treated with Simvastatin] results in decreased expression of LPA protein affects cotreatment
/ decreases expression
protein 18471454
D009525 4018 LPA
AK38
APOA
LP
lipoprotein, Lp(a) (EC:3.4.21.-) Niacin results in decreased expression of LPA protein decreases expression
protein 12099974
12200755
12685616
15159270
D009525 5594 MAPK1
ERK
ERK2
ERT1
MAPK2
P42MAPK
PRKM1
PRKM2
p38
p40
p41
p41mapk
mitogen-activated protein kinase 1 (EC:2.7.11.24) [Niacin binds to and results in increased activity of HCAR2 protein] which results in increased phosphorylation of MAPK1 protein affects binding
/ increases activity
/ increases phosphorylation
protein 16389067
D009525 5594 MAPK1
ERK
ERK2
ERT1
MAPK2
P42MAPK
PRKM1
PRKM2
p38
p40
p41
p41mapk
mitogen-activated protein kinase 1 (EC:2.7.11.24) [Niacin binds to and results in increased activity of HCAR3 protein] which results in increased phosphorylation of MAPK1 protein affects binding
/ increases activity
/ increases phosphorylation
protein 16389067
D009525 5594 MAPK1
ERK
ERK2
ERT1
MAPK2
P42MAPK
PRKM1
PRKM2
p38
p40
p41
p41mapk
mitogen-activated protein kinase 1 (EC:2.7.11.24) Pertussis Toxin inhibits the reaction [Niacin results in increased phosphorylation of MAPK1 protein] decreases reaction
/ increases phosphorylation
protein 16389067
D009525 5595 MAPK3
ERK-1
ERK1
ERT2
HS44KDAP
HUMKER1A
P44ERK1
P44MAPK
PRKM3
p44-ERK1
p44-MAPK
mitogen-activated protein kinase 3 (EC:2.7.11.24) [Niacin binds to and results in increased activity of HCAR2 protein] which results in increased phosphorylation of MAPK3 protein affects binding
/ increases activity
/ increases phosphorylation
protein 16389067
D009525 5595 MAPK3
ERK-1
ERK1
ERT2
HS44KDAP
HUMKER1A
P44ERK1
P44MAPK
PRKM3
p44-ERK1
p44-MAPK
mitogen-activated protein kinase 3 (EC:2.7.11.24) [Niacin binds to and results in increased activity of HCAR3 protein] which results in increased phosphorylation of MAPK3 protein affects binding
/ increases activity
/ increases phosphorylation
protein 16389067
D009525 5595 MAPK3
ERK-1
ERK1
ERT2
HS44KDAP
HUMKER1A
P44ERK1
P44MAPK
PRKM3
p44-ERK1
p44-MAPK
mitogen-activated protein kinase 3 (EC:2.7.11.24) Pertussis Toxin inhibits the reaction [Niacin results in increased phosphorylation of MAPK3 protein] decreases reaction
/ increases phosphorylation
protein 16389067
D009525 10062 NR1H3
LXR-a
LXRA
RLD-1
nuclear receptor subfamily 1, group H, member 3 Niacin results in increased expression of NR1H3 mRNA increases expression
mRNA 15037193
D009525 10062 NR1H3
LXR-a
LXRA
RLD-1
nuclear receptor subfamily 1, group H, member 3 PPARG protein promotes the reaction [Niacin results in increased expression of NR1H3 mRNA] increases expression
/ increases reaction
mRNA 15037193
D009525 142 PARP1
ADPRT
ADPRT_1
ADPRT1
ARTD1
PARP
PARP-1
PPOL
pADPRT-1
poly (ADP-ribose) polymerase 1 (EC:2.4.2.30) [Niacin co-treated with Ubiquinone co-treated with Riboflavin] results in increased expression of PARP1 protein affects cotreatment
/ increases expression
protein 18377693
D009525 5175 PECAM1
CD31
CD31/EndoCAM
GPIIA'
PECA1
PECAM-1
endoCAM
platelet/endothelial cell adhesion molecule 1 Niacin inhibits the reaction [TNF protein results in increased expression of PECAM1 protein] decreases reaction
/ increases expression
protein 19159436
D009525 5175 PECAM1
CD31
CD31/EndoCAM
GPIIA'
PECA1
PECAM-1
endoCAM
platelet/endothelial cell adhesion molecule 1 Niacin results in decreased expression of PECAM1 protein decreases expression
protein 19159436
D009525 7941 PLA2G7
LDL-PLA2
LP-PLA2
PAFAD
PAFAH
phospholipase A2, group VII (platelet-activating factor acetylhydrolase, plasma) (EC:3.1.1.47) Niacin results in decreased expression of PLA2G7 protein decreases expression
protein 16950175
D009525 5465 PPARA
NR1C1
PPAR
PPARalpha
hPPAR
peroxisome proliferator-activated receptor alpha Niacin results in increased expression of PPARA mRNA increases expression
mRNA 18602814
D009525 5468 PPARG
CIMT1
GLM1
NR1C3
PPARG1
PPARG2
PPARgamma
peroxisome proliferator-activated receptor gamma 4-benzhydryloxy-1-(3-(1H-tetrazol-5-yl-)-propyl)piperidine inhibits the reaction [Niacin results in increased activity of PPARG protein] decreases reaction
/ increases activity
protein 16386710
D009525 5468 PPARG
CIMT1
GLM1
NR1C3
PPARG1
PPARG2
PPARgamma
peroxisome proliferator-activated receptor gamma Aspirin inhibits the reaction [Niacin results in increased activity of PPARG protein] decreases reaction
/ increases activity
protein 16386710
D009525 5468 PPARG
CIMT1
GLM1
NR1C3
PPARG1
PPARG2
PPARgamma
peroxisome proliferator-activated receptor gamma HCAR2 protein promotes the reaction [Niacin results in increased expression of and results in increased activity of PPARG protein] increases activity
/ increases expression
/ increases reaction
protein 16386710
D009525 5468 PPARG
CIMT1
GLM1
NR1C3
PPARG1
PPARG2
PPARgamma
peroxisome proliferator-activated receptor gamma HCAR3 protein promotes the reaction [Niacin results in increased activity of PPARG protein] increases activity
/ increases reaction
protein 16386710
D009525 5468 PPARG
CIMT1
GLM1
NR1C3
PPARG1
PPARG2
PPARgamma
peroxisome proliferator-activated receptor gamma Niacin results in increased expression of and results in increased activity of PPARG protein increases activity
/ increases expression
protein 15037193
16386710
D009525 5468 PPARG
CIMT1
GLM1
NR1C3
PPARG1
PPARG2
PPARgamma
peroxisome proliferator-activated receptor gamma Niacin results in increased expression of PPARG mRNA increases expression
mRNA 15037193
19131065
D009525 5468 PPARG
CIMT1
GLM1
NR1C3
PPARG1
PPARG2
PPARgamma
peroxisome proliferator-activated receptor gamma PPARG protein promotes the reaction [Niacin results in increased expression of NR1H3 mRNA] increases expression
/ increases reaction
protein 15037193
D009525 5468 PPARG
CIMT1
GLM1
NR1C3
PPARG1
PPARG2
PPARgamma
peroxisome proliferator-activated receptor gamma PTGDS protein promotes the reaction [Niacin results in increased activity of PPARG protein] increases activity
/ increases reaction
protein 16386710
D009525 5468 PPARG
CIMT1
GLM1
NR1C3
PPARG1
PPARG2
PPARgamma
peroxisome proliferator-activated receptor gamma PTGS1 protein promotes the reaction [Niacin results in increased activity of PPARG protein] increases activity
/ increases reaction
protein 16386710
D009525 10891 PPARGC1A
LEM6
PGC-1(alpha)
PGC-1v
PGC1
PGC1A
PPARGC1
peroxisome proliferator-activated receptor gamma, coactivator 1 alpha Niacin results in increased expression of PPARGC1A mRNA increases expression
mRNA 23056435
D009525 5563 PRKAA2
AMPK
AMPK2
AMPKa2
PRKAA
protein kinase, AMP-activated, alpha 2 catalytic subunit (EC:2.7.11.1 2.7.11.27 2.7.11.31) Niacin results in increased activity of PRKAA2 protein increases activity
protein 14749208
D009525 5729 PTGDR
AS1
ASRT1
DP
DP1
PTGDR1
prostaglandin D2 receptor (DP) [MK-0524 binds to and results in decreased activity of PTGDR protein] which results in decreased susceptibility to Niacin affects binding
/ decreases activity
/ decreases response to substance
protein 17392721
D009525 5730 PTGDS
L-PGDS
LPGDS
PDS
PGD2
PGDS
PGDS2
prostaglandin D2 synthase 21kDa (brain) (EC:5.3.99.2) PTGDS protein promotes the reaction [Niacin results in increased activity of PPARG protein] increases activity
/ increases reaction
protein 16386710
D009525 5742 PTGS1
COX1
COX3
PCOX1
PES-1
PGG/HS
PGHS-1
PGHS1
PHS1
PTGHS
prostaglandin-endoperoxide synthase 1 (prostaglandin G/H synthase and cyclooxygenase) (EC:1.14.99.1) PTGS1 protein promotes the reaction [Niacin results in increased activity of PPARG protein] increases activity
/ increases reaction
protein 16386710
D009525 5970 RELA
NFKB3
p65
v-rel avian reticuloendotheliosis viral oncogene homolog A Niacin inhibits the reaction [TNF protein results in increased activity of RELA protein] decreases reaction
/ increases activity
protein 18550065
D009525 56729 RETN
ADSF
FIZZ3
RETN1
RSTN
XCP1
resistin Niacin results in decreased expression of RETN protein decreases expression
protein 16979396
D009525 949 SCARB1
CD36L1
CLA-1
CLA1
HDLQTL6
SR-BI
SRB1
scavenger receptor class B, member 1 Aspirin inhibits the reaction [Niacin results in increased expression of SCARB1 mRNA] decreases reaction
/ increases expression
mRNA 15037193
D009525 949 SCARB1
CD36L1
CLA-1
CLA1
HDLQTL6
SR-BI
SRB1
scavenger receptor class B, member 1 Niacin promotes the reaction [SCARB1 protein results in increased export of Cholesterol, HDL] increases export
/ increases reaction
protein 21291703
D009525 949 SCARB1
CD36L1
CLA-1
CLA1
HDLQTL6
SR-BI
SRB1
scavenger receptor class B, member 1 Niacin results in increased expression of SCARB1 mRNA increases expression
mRNA 15037193
D009525 949 SCARB1
CD36L1
CLA-1
CLA1
HDLQTL6
SR-BI
SRB1
scavenger receptor class B, member 1 Ro 31-8220 inhibits the reaction [Niacin results in increased expression of SCARB1 mRNA] decreases reaction
/ increases expression
mRNA 15037193
D009525 5054 SERPINE1
PAI
PAI-1
PAI1
PLANH1
serpin peptidase inhibitor, clade E (nexin, plasminogen activator inhibitor type 1), member 1 Niacin inhibits the reaction [TGFB1 protein results in increased expression of SERPINE1 protein] decreases reaction
/ increases expression
protein 16916501
D009525 7040 TGFB1
CED
DPD1
LAP
TGFB
TGFbeta
transforming growth factor, beta 1 Niacin inhibits the reaction [Silicon Dioxide results in increased expression of TGFB1 mRNA] decreases reaction
/ increases expression
mRNA 19337903
D009525 7040 TGFB1
CED
DPD1
LAP
TGFB
TGFbeta
transforming growth factor, beta 1 Niacin inhibits the reaction [Silicon Dioxide results in increased expression of TGFB1 protein] decreases reaction
/ increases expression
protein 19337903
D009525 7040 TGFB1
CED
DPD1
LAP
TGFB
TGFbeta
transforming growth factor, beta 1 Niacin inhibits the reaction [TGFB1 protein results in increased expression of SERPINE1 protein] decreases reaction
/ increases expression
protein 16916501
D009525 7124 TNF
DIF
TNF-alpha
TNFA
TNFSF2
tumor necrosis factor Niacin inhibits the reaction [TNF protein results in increased activity of RELA protein] decreases reaction
/ increases activity
protein 18550065
D009525 7124 TNF
DIF
TNF-alpha
TNFA
TNFSF2
tumor necrosis factor Niacin inhibits the reaction [TNF protein results in increased expression of CCL2 protein] decreases reaction
/ increases expression
protein 18550065
D009525 7124 TNF
DIF
TNF-alpha
TNFA
TNFSF2
tumor necrosis factor Niacin inhibits the reaction [TNF protein results in increased expression of ICAM1 mRNA] decreases reaction
/ increases expression
protein 16916501
19159436
D009525 7124 TNF
DIF
TNF-alpha
TNFA
TNFSF2
tumor necrosis factor Niacin inhibits the reaction [TNF protein results in increased expression of PECAM1 protein] decreases reaction
/ increases expression
protein 19159436
D009525 7124 TNF
DIF
TNF-alpha
TNFA
TNFSF2
tumor necrosis factor Niacin inhibits the reaction [TNF protein results in increased expression of VCAM1 mRNA] decreases reaction
/ increases expression
protein 18550065
D009525 7124 TNF
DIF
TNF-alpha
TNFA
TNFSF2
tumor necrosis factor [Ubiquinone co-treated with Niacin co-treated with Riboflavin] promotes the reaction [Tamoxifen results in decreased expression of TNF protein] affects cotreatment
/ decreases expression
/ increases reaction
protein 17516992
D009525 7412 VCAM1
CD106
INCAM-100
vascular cell adhesion molecule 1 Niacin inhibits the reaction [TNF protein results in increased expression of VCAM1 mRNA] decreases reaction
/ increases expression
mRNA 18550065
D009525 7448 VTN
V75
VN
VNT
vitronectin Niacin results in increased expression of VTN protein increases expression
protein 20539903

Related Disease

Diseases related to proteins in ChEMBL interactions

OMIM (38)

OMIM preferred title UniProt
#100100 Abdominal muscles, absence of, with urinary tract abnormality and cryptorchidism P20309
#103780 Alcohol dependence P08172
P14416
P31645
#614373 Amyotrophic lateral sclerosis 16, juvenile; als16 Q99720
#602025 Body mass index quantitative trait locus 9; bmiq9 P41968
#300615 Brunner syndrome P21397
#212140 Carnitine deficiency, systemic primary; cdsp O76082
#162800 Cyclic neutropenia P08246
#612522 Diabetes mellitus, insulin-dependent, 22; iddm22 P51681
#609535 Drug metabolism, poor, cyp2c19-related P33261
#608902 Drug metabolism, poor, cyp2d6-related P10635
#615363 Estrogen resistance; estrr P03372
#613659 Gastric cancer P04626
#137215 Gastric cancer, hereditary diffuse; hdgc P04626
#231095 Ghosal hematodiaphyseal dysplasia; ghdd P24557
#137800 Glioma susceptibility 1; glm1 P04626
#232300 Glycogen storage disease ii P10253
#609423 Human immunodeficiency virus type 1, susceptibility to P41597
P51681
#603932 Intervertebral disc disease; idd P14780
#613688 Long qt syndrome 2; lqt2 Q12809
#211980 Lung cancer P00533
P04626
#608516 Major depressive disorder; mdd P08172
%300852 Mental retardation, x-linked 88; mrx88 P50052
#613073 Metaphyseal anadysplasia 2; mandp2 P14780
#126200 Multiple sclerosis, susceptibility to; ms P08575
#159900 Myoclonic dystonia P14416
#202700 Neutropenia, severe congenital, 1, autosomal dominant; scn1 P08246
#601665 Obesity P32245
#164230 Obsessive-compulsive disorder; ocd P31645
#604715 Orthostatic intolerance P23975
#259730 Osteopetrosis, autosomal recessive 3; optb3 P00918
#167000 Ovarian cancer P04626
#613135 Parkinsonism-dystonia, infantile; pkdys Q01959
#607276 Resting heart rate, variation in P08588
#608971 Severe combined immunodeficiency, autosomal recessive, t cell-negative, b cell-positive, nk cell-positive P08575
#609620 Short qt syndrome 1; sqt1 Q12809
#190300 Tremor, hereditary essential, 1; etm1 P35462
#610379 West nile virus, susceptibility to P51681
#112100 Yt blood group antigen P22303

KEGG DISEASE (34)

KEGG disease name UniProt
H00286 Crohn's disease O76082 (related)
H00525 Disorders of fatty-acid oxidation O76082 (related)
H00016 Oral cancer P00533 (related)
P00533 (marker)
H00017 Esophageal cancer P00533 (related)
P35354 (related)
H00018 Gastric cancer P00533 (related)
P04626 (related)
H00022 Bladder cancer P00533 (related)
P04626 (related)
H00028 Choriocarcinoma P00533 (related)
P03956 (related)
P04626 (related)
H00030 Cervical cancer P00533 (related)
P04626 (related)
H00042 Glioma P00533 (related)
P00533 (marker)
H00055 Laryngeal cancer P00533 (related)
P00533 (marker)
H00241 Combined proximal and distal renal tubular acidosis (RTA type 3) P00918 (related)
H00436 Osteopetrosis P00918 (related)
H00026 Endometrial Cancer P03372 (marker)
P04626 (related)
Q92731 (marker)
H00599 46,XX disorders of sex development (Disorders related to androgen excess) P04150 (related)
H00019 Pancreatic cancer P04626 (related)
H00027 Ovarian cancer P04626 (related)
H00031 Breast cancer P04626 (related)
P04626 (marker)
H00046 Cholangiocarcinoma P04626 (related)
P35354 (related)
H00093 Combined immunodeficiencies (CIDs) P06239 (related)
H00079 Asthma P07550 (related)
H00100 Neutropenic disorders P08246 (related)
H00091 T-B+Severe combined immunodeficiencies (SCIDs) P08575 (related)
H00036 Osteosarcoma P08684 (marker)
H00069 Glycogen storage diseases (GSD) P10253 (related)
H01205 Coumarin resistance P11712 (related)
H00025 Penile cancer P14780 (related)
P35354 (related)
H00479 Metaphyseal dysplasias P14780 (related)
H00548 Brunner syndrome P21397 (related)
H01031 Orthostatic intolerance (OI) P23975 (related)
H00490 Diaphyseal dysplasia with anemia (Ghosal) P24557 (related)
H01171 Poor drug metabolism (PM) P33261 (related)
H00480 Non-syndromic X-linked mental retardation P50052 (related)
H00720 Long QT syndrome Q12809 (related)
H00725 Short QT syndrome Q12809 (related)

Diseases related to CTD interactions

110 disease from interactions of metabolites

MeSH disease OMIM compound disease name evidence type reference
pmid
D000138 D009525 Acidosis marker/mechanism
17418450
D000140 D009525 Acidosis, Lactic marker/mechanism
2054009
D000544 D009525 Alzheimer Disease therapeutic
15258207
D000550 D009525 Amblyopia marker/mechanism
8593127
D000749 D009525 Anemia, Megaloblastic therapeutic
16353713
D001161 D009525 Arteriosclerosis therapeutic
11701466
D050197 D009525 Atherosclerosis therapeutic
12487376
15537681
15808326
19092644
20399059
21317532
D001943 D009525 Breast Neoplasms therapeutic
15766922
17268082
D002318 D009525 Cardiovascular Diseases therapeutic
15642562
D002340 D009525 Carotid Artery Diseases therapeutic
17076985
D002386 D009525 Cataract therapeutic
11438049
D002418 D009525 Cattle Diseases therapeutic
6497141
D023341 D009525 Chills marker/mechanism
14614780
D002779 D009525 Cholestasis marker/mechanism
6823602
D002780 D009525 Cholestasis, Intrahepatic marker/mechanism
8124850
D043171 D009525 Chromosomal Instability therapeutic
12379464
D002971 D009525 Cleft Lip therapeutic
14991264
D002972 D009525 Cleft Palate therapeutic
14991264
D003072 D009525 Cognition Disorders therapeutic
15258207
D003324 D009525 Coronary Artery Disease therapeutic
11597936
12094204
12562840
18822413
19915217
D003327 D009525 Coronary Disease therapeutic
11472706
11757504
15929991
D023921 D009525 Coronary Stenosis therapeutic
12637338
15657157
D003693 D009525 Delirium marker/mechanism
2054009
D003920 D009525 Diabetes Mellitus therapeutic
12200755
D003925 D009525 Diabetic Angiopathies therapeutic
20667937
D004244 D009525 Dizziness marker/mechanism
17418450
D056486 D009525 Drug-Induced Liver Injury marker/mechanism
1988755
2355439
2355446
3547004
3680913
6823602
7873090
8505497
8593127
10096345
17418450
D064420 D009525 Drug-Related Side Effects and Adverse Reactions marker/mechanism
2017280
D020820 D009525 Dyskinesias marker/mechanism
2054009
D050171 D009525 Dyslipidemias therapeutic
9824032
11472706
11701466
11765300
11835917
12099974
12123399
12200755
12804728
15219522
15307011
15929991
16230877
16487912
16690463
17002798
17156651
17190373
17302378
17319473
18230960
18422390
18471454
19019811
19092644
19166443
19331435
20518948
20948500
21098376
21121498
21276961
21291812
D004415 D009525 Dyspepsia marker/mechanism
16400392
D004487 D009525 Edema marker/mechanism
7880795
D019446 D009525 Endotoxemia therapeutic
20975550
D004890 D009525 Erythema marker/mechanism
11721583
D005076 D009525 Exanthema marker/mechanism
11868059
16669604
D005094 D009525 Exophthalmos marker/mechanism
7880795
D005128 D009525 Eye Diseases marker/mechanism
15488795
D005141 D009525 Eyelid Diseases marker/mechanism
7880795
D005234 D009525 Fatty Liver marker/mechanism
10096345
D005483 D009525 Flushing marker/mechanism
3547004
8593127
11501224
11571498
11721583
11853118
11868059
12123399
12502030
12648730
12650743
12837522
14614780
15380405
15539964
15653014
15673472
15885994
16322797
16400392
16466614
16600583
16837062
16936284
17008386
17156651
17190373
17323787
17392721
17459487
17890071
17904833
17993463
18189062
18203758
18223672
18308010
18410350
18420099
18422390
18471454
18784348
18831918
19166443
19243712
19243714
19246721
19301936
19309152
19331435
19454860
19521894
19576324
19602880
19833861
19864122
20107202
20116108
20152243
20184326
20212073
20417059
20533755
20855072
D005767 D009525 Gastrointestinal Diseases marker/mechanism
3547004
14614780
D005923 D009525 Glomerulosclerosis, Focal Segmental therapeutic
19420110
D018149 D009525 Glucose Intolerance marker/mechanism
8593127
15307011
D006073 D009525 Gout marker/mechanism
8593127
D006501 D009525 Hepatic Encephalopathy marker/mechanism
2355439
D006505 D009525 Hepatitis marker/mechanism
1988755
8593127
D006937 D009525 Hypercholesterolemia therapeutic
2054009
2492189
2929636
3174043
3275891
3680913
8124850
8593127
12487376
12788145
12804729
15342288
15808326
17611329
18471454
19166443
19911216
21291812
D006943 D009525 Hyperglycemia marker/mechanism
8593127
20377808
D020138 D009525 HYPERHOMOCYSTEINEMIA marker/mechanism
11895163
D006950 D009525 Hyperlipidemia, Familial Combined therapeutic
15539964
20152243
D006949 D009525 Hyperlipidemias therapeutic
7880795
12685616
12767421
15564652
16931439
18519840
18566298
D006951 D009525 Hyperlipoproteinemias therapeutic
11498460
15342288
17425952
17611329
19240310
20377808
20831686
20855072
D006938 D009525 Hyperlipoproteinemia Type II therapeutic
906593
2492189
8729588
15159270
18420099
19496270
19947811
20152243
D006952 D009525 Hyperlipoproteinemia Type III therapeutic
12506591
D006954 D009525 Hyperlipoproteinemia Type V therapeutic
906593
D006973 D009525 Hypertension therapeutic
18374418
19243712
19420110
19878707
21128910
D015228 D009525 Hypertriglyceridemia therapeutic
4685092
8593127
11498460
11701466
12767421
15159270
15304625
17425952
17668211
18420099
18422390
18471454
20371660
20377808
20518948
20533755
20855072
D052456 D009525 Hypoalphalipoproteinemias therapeutic
7942568
11498460
11701466
11757504
12094204
15537681
15539964
15657157
16407706
18993152
20152243
D007003 D009525 Hypoglycemia marker/mechanism
therapeutic
6497141
17418450
D018476 D009525 Hypokinesia therapeutic
16669604
D007009 D009525 Hypolipoproteinemias therapeutic
12767421
19131065
19240310
21045170
D007022 D009525 Hypotension marker/mechanism
16496499
19054161
D020244 D009525 Infarction, Middle Cerebral Artery therapeutic
20451219
D007249 D009525 Inflammation therapeutic
19420110
20167660
D007333 D009525 Insulin Resistance marker/mechanism
19405044
D002546 D009525 Ischemic Attack, Transient therapeutic
20208032
D007565 D009525 Jaundice marker/mechanism
8124850
D007634 D009525 Keratitis marker/mechanism
7880795
D007662 D009525 Ketosis therapeutic
6497141
D007676 D009525 Kidney Failure, Chronic therapeutic
19878707
D007938 D009525 Leukemia therapeutic
19372544
D015470 D009525 Leukemia, Myeloid, Acute marker/mechanism
18444158
D008060 D009525 Lipodystrophy therapeutic
12218390
D017114 D009525 Liver Failure, Acute marker/mechanism
1771885
2355439
2665592
3680913
D055370 D009525 Lung Injury therapeutic
15856184
D008269 D009525 Macular Edema marker/mechanism
7880795
12692483
16767207
D047508 D009525 Massive Hepatic Necrosis marker/mechanism
1771885
D024821 D009525 Metabolic Syndrome X therapeutic
17935553
D008881 D009525 Migraine Disorders therapeutic
15673472
D009127 D009525 Muscle Rigidity therapeutic
16669604
D009135 D009525 Muscular Diseases marker/mechanism
2929636
3076126
7942568
8593127
8729588
19496270
D009203 D009525 Myocardial Infarction therapeutic
7942568
16461040
20208032
D017202 D009525 Myocardial Ischemia marker/mechanism
2011995
D015428 D009525 Myocardial Reperfusion Injury therapeutic
10924076
19027847
D009325 D009525 Nausea marker/mechanism
15673472
17418450
D009336 D009525 Necrosis marker/mechanism
7873090
8593127
D009369 D009525 Neoplasms therapeutic
6061664
D009798 D009525 Ocular Hypertension marker/mechanism
18717445
D010146 D009525 Pain marker/mechanism
therapeutic
9824032
21121498
D010292 D009525 Paresthesia marker/mechanism
15539964
D010383 D009525 Pellagra therapeutic
15242145
15953078
16519110
16713031
17712518
19061687
19155950
21128910
D010523 D009525 Peripheral Nervous System Diseases marker/mechanism
9671841
D010612 D009525 Pharyngitis marker/mechanism
15539964
D011014 D009525 Pneumonia therapeutic
20975550
D011507 D009525 Proteinuria therapeutic
19420110
19878707
D011537 D009525 Pruritus marker/mechanism
8124850
8593127
14614780
15539964
20855072
D012162 D009525 Retinal Degeneration marker/mechanism
8593127
D012164 D009525 Retinal Diseases marker/mechanism
3174043
12788145
D012817 D009525 Signs and Symptoms, Digestive marker/mechanism
8593127
17156651
D012859 D009525 Sjogren's Syndrome marker/mechanism
7880795
D012871 D009525 Skin Diseases marker/mechanism
3547004
D012877 D009525 Skin Manifestations marker/mechanism
17418450
D016135 D009525 Spinal Dysraphism marker/mechanism
15173422
D020521 D009525 Stroke therapeutic
17557352
19223914
20208032
20671245
D013575 D009525 Syncope marker/mechanism
15673472
D018781 D009525 Tension-Type Headache therapeutic
15673472
D014098 D009525 Toothache marker/mechanism
9824032
D014786 D009525 Vision Disorders marker/mechanism
3174043
7880795
12788145
D014839 D009525 Vomiting marker/mechanism
17418450
D014947 D009525 Wounds and Injuries therapeutic
20045543